The stock of Baxter International Inc (NYSE:BAX) is a huge mover today! About 1.41M shares traded hands. Baxter International Inc (NYSE:BAX) has risen 14.07% since April 11, 2016 and is uptrending. It has outperformed by 7.92% the S&P500.
The move comes after 9 months positive chart setup for the $26.40 billion company. It was reported on Nov, 11 by Barchart.com. We have $73.27 PT which if reached, will make NYSE:BAX worth $14.52 billion more.
Baxter International Inc (NYSE:BAX) Ratings Coverage
Out of 11 analysts covering Baxter International (NYSE:BAX), 5 rate it a “Buy”, 0 “Sell”, while 6 “Hold”. This means 45% are positive. Baxter International has been the topic of 20 analyst reports since July 30, 2015 according to StockzIntelligence Inc. The stock of Baxter International Inc (NYSE:BAX) earned “Overweight” rating by Piper Jaffray on Thursday, April 14. The company was initiated on Tuesday, September 22 by UBS. The firm earned “Sector Perform” rating on Wednesday, February 3 by RBC Capital Markets. The stock has “Overweight” rating given by Barclays Capital on Thursday, September 15. The company was initiated on Monday, November 16 by Piper Jaffray. The rating was initiated by Evercore with “Buy” on Wednesday, May 4. The company was initiated on Thursday, October 13 by Wells Fargo. Barclays Capital maintained the stock with “Overweight” rating in Tuesday, August 11 report. As per Monday, June 6, the company rating was reinitiated by JP Morgan. As per Monday, August 10, the company rating was reinitiated by Credit Suisse.
According to Zacks Investment Research, “Baxter engages in the worldwide development, manufacture and distribution of a diversified line of products, systems and services used primarily in the health-care field. The company’s products are used by hospitals, clinical and medical research laboratories, blood and dialysis centers, rehabilitation centers, nursing homes, doctors’ offices and by patients, at home, under physician supervision.”
Insitutional Activity: The institutional sentiment decreased to 0.68 in Q2 2016. Its down 0.33, from 1.01 in 2016Q1. The ratio worsened, as 75 funds sold all Baxter International Inc shares owned while 363 reduced positions. 67 funds bought stakes while 233 increased positions. They now own 437.24 million shares or 6.33% less from 466.81 million shares in 2016Q1.
Amica Retiree Med Tru accumulated 0.12% or 3,040 shares. Bahl Gaynor has invested 0.01% of its portfolio in Baxter International Inc (NYSE:BAX). Parkwood holds 0.04% or 5,453 shares in its portfolio. Oakworth Cap last reported 24,010 shares in the company. Garrison Corporation last reported 5,384 shares in the company. Bluecrest Mgmt Ltd has invested 0.02% of its portfolio in Baxter International Inc (NYSE:BAX). The New Mexico-based New Mexico Educational Retirement Board has invested 0.13% in Baxter International Inc (NYSE:BAX). Kanaly last reported 161 shares in the company. Ironwood Fincl Ltd Liability Com accumulated 71 shares or 0% of the stock. Tweedy Browne Com Ltd Liability Corp has 2.39M shares for 3.04% of their US portfolio. Moreover, Morgan Dempsey Capital Mgmt Limited Liability Company has 0% invested in Baxter International Inc (NYSE:BAX) for 45 shares. Lipe And Dalton has 83,313 shares for 2.6% of their US portfolio. Putnam Invests Limited Com has invested 0.06% of its portfolio in Baxter International Inc (NYSE:BAX). Arrow Fincl Corporation holds 3,875 shares or 0.05% of its portfolio. Argyle Cap Mgmt accumulated 1.13% or 58,904 shares.
Insider Transactions: Since May 23, 2016, the stock had 1 insider purchase, and 0 insider sales for $499,790 net activity. Shares for $499,790 were bought by ALMEIDA JOSE E.
Another recent and important Baxter International Inc (NYSE:BAX) news was published by Fool.com which published an article titled: “Baxter International Inc Gets More Efficient” on October 26, 2016.
BAX Company Profile
Baxter International Inc., incorporated on October 19, 1931, through its subsidiaries, provides a portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics, and pharmacy automation, software and services. The Firm operates through two divisions: Hospital Products and Renal. The Company’s products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices and by patients at home under physician supervision. The Firm makes products in approximately 30 countries and sells them in approximately 120 countries.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.